Primary Gout With Hyperuricemia in Adults
Conditions
Brief summary
The study is being conducted to evaluate the efficacy and safety of HR091506 tablets for treatment of primary gout with hyperuricemia in adults, and to compare the results with febuxostat tablets in the same doses.
Interventions
HR091506 tablets 40mg qd + placebo of febuxostat tablets 40mg qd in Week 1 and 2, HR091506 tablets 80mg qd + placebo of febuxostat tablets 80mg qd in Week 3 and 4
febuxostat tablets 40mg qd + placebo of HR091506 tablets 40mg qd in Week 1 and 2, febuxostat tablets 80mg qd + placebo of HR091506 tablets 80mg qd in Week 3 and 4
Sponsors
Jiangsu HengRui Medicine Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Intervention model description
HR091506 tablets compared with febuxostat tablets
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. 18 - 65 years old, male or female. 2. BMI: 18.0 - 30 kg/m2. 3. Meet the 2015 ACR (American College of Rheumatology) gout classification criteria. 4. Fasting serum uric acid ≥480 μmol/L on 2 different days during the screening period. 5. Willing to use contraceptive measures during the study. 6. Able and willing to provide a written informed consent.
Exclusion criteria
1. History of acute gout attack within 4 weeks before randomization. 2. Urinary calculi diagnosed by B-ultrasound within 4 weeks before randomization. 3. Subjects who have undergone major surgery or organ transplantation within 3 months before randomization. 4. Major cardiovascular disease within 6 months before randomization. 5. History of chronic infection or recurrent infection within 1 year before randomization. 6. History of malignant tumor or current history of combined malignant tumor within 5 years before screening. 7. History of secondary hyperuricemia, refractory gout, or xanthine metabolism disorder. 8. Subjects with poorly controlled blood pressure or diabetes mellitus. 9. History of chronic diffuse connective tissue disease and/or massively elevated urate diseases and/or untreated clinically significant thyroid disease. 10. History of diseases that may affect the in vivo process, safety evaluation, or subjects' participation in the research. 11. Abnormal laboratory tests that may affect subjects participating in the research. 12. Combined use of prohibited drugs. 13. Allergic to ingredient or component of the experimental drug. 14. Participated in other clinical trials within 1 month before randomization. 15. Pregnant or nursing women. 16. History of drug abuse, drug use and/or excessive drinking within 1 year before screening. 17. The inestigators determined that other conditions were inappropriate for participation in this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The proportion of subjects with serum uric acid level < 360μmol/L on Day 15. | on Day 15. |
| Proportion of subjects with serum uric acid level < 360μmol/L at test of cure (TOC) | Test of cure, defined as the day after end of treatment, equivalent to Study Day 15 or 29 |
Secondary
| Measure | Time frame |
|---|---|
| The proportion of subjects with serum uric acid level < 360μmol/L on Day 29. | on Day 29. |
| The proportion of subjects with serum uric acid level < 300μmol/L on Day 29. | on Day 29. |
| The proportion of subjects with serum uric acid level < 300μmol/L on Day 15. | on Day 15. |
| Change of serum uric acid level from baseline on Day 29 | from baseline on Day 29 |
| Change of serum uric acid level from baseline on Day 15 | from baseline on Day 15 |
| Proportion of subjects with serum uric acid level < 360μmol/L at TOC | Test of cure, defined as the day after end of treatment, equivalent to Study Day 15 or 29 |
Contacts
Primary ContactHuize Han
Outcome results
None listed